Advertisement
Screener

QUIDELORTHO CORP (QDEL) Investing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

QUIDELORTHO CORP Investing Cash Flow

QUIDELORTHO CORP (QDEL) reported Investing Cash Flow of -$141.30 million for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-07

  • QUIDELORTHO CORP net cash provided by (used in) investing activities for the quarter ending 2026-06-28 was -$107.30M.
  • QUIDELORTHO CORP net cash provided by (used in) investing activities for the quarter ending 2026-03-29 was -$34.00M.
  • QUIDELORTHO CORP net cash provided by (used in) investing activities for the quarter ending 2025-12-28 was -$49.60M.
  • QUIDELORTHO CORP net cash provided by (used in) investing activities for the quarter ending 2025-09-28 was -$53.90M.
  • QUIDELORTHO CORP net cash provided by (used in) investing activities for fiscal 2025 was -$192.70M.
  • QUIDELORTHO CORP net cash provided by (used in) investing activities for fiscal 2024 was -$149.90M.
  • QUIDELORTHO CORP net cash provided by (used in) investing activities for fiscal 2023 was -$187.60M.
  • QUIDELORTHO CORP net cash provided by (used in) investing activities for fiscal 2023 was -$1.64B.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 12 month
2026-06-28-$107.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
-$141.30M
10-Q · filed 2026-08-07
-$190.90M
derived: sum of 3 quarters · filed 2026-08-07
-$244.80M
derived: sum of 4 quarters · filed 2026-08-07
2026-03-29-$34.00M
10-Q · filed 2026-05-06
-$83.60M
derived: sum of 2 quarters · filed 2026-05-06
-$137.50M
derived: sum of 3 quarters · filed 2026-05-06
-$170.50M
derived: sum of 4 quarters · filed 2026-08-07
2025-12-28-$49.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
-$103.50M
derived: sum of 2 quarters · filed 2026-02-19
-$136.50M
derived: sum of 3 quarters · filed 2026-08-07
-$192.70M
10-K · filed 2026-02-19
2025-09-28-$53.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$86.90M
derived: sum of 2 quarters · filed 2026-08-07
-$143.10M
10-Q · filed 2025-11-06
-$181.00M
derived: sum of 4 quarters · filed 2026-08-07
2025-06-29-$33.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
-$89.20M
10-Q · filed 2026-08-07
-$127.10M
derived: sum of 3 quarters · filed 2026-08-07
-$183.60M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-30-$56.20M
10-Q · filed 2026-05-06
-$94.10M
derived: sum of 2 quarters · filed 2026-05-06
-$150.60M
derived: sum of 3 quarters · filed 2026-05-06
-$185.90M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-29-$37.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
-$94.40M
derived: sum of 2 quarters · filed 2026-02-19
-$129.70M
derived: sum of 3 quarters · filed 2026-02-19
-$149.90M
10-K · filed 2026-02-19
2024-09-29-$56.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$91.80M
derived: sum of 2 quarters · filed 2025-11-06
-$112.00M
10-Q · filed 2025-11-06
-$167.10M
derived: sum of 4 quarters · filed 2026-02-19
2024-06-30-$35.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$55.50M
10-Q · filed 2025-08-06
-$110.60M
derived: sum of 3 quarters · filed 2026-02-19
-$131.90M
derived: sum of 4 quarters · filed 2026-02-19
2024-03-31-$20.20M
10-Q · filed 2025-05-08
-$75.30M
derived: sum of 2 quarters · filed 2026-02-19
-$96.60M
derived: sum of 3 quarters · filed 2026-02-19
-$138.90M
derived: sum of 4 quarters · filed 2026-02-19
2023-12-31-$55.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
-$76.40M
derived: sum of 2 quarters · filed 2026-02-19
-$118.70M
derived: sum of 3 quarters · filed 2026-02-19
-$187.60M
10-K · filed 2026-02-19
2023-10-01-$21.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
-$63.60M
derived: sum of 2 quarters · filed 2024-11-08
-$132.50M
10-Q · filed 2024-11-08
-$191.80M
derived: sum of 4 quarters · filed 2025-02-27
2023-07-02-$42.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
-$111.20M
10-Q · filed 2024-08-01
-$170.50M
derived: sum of 3 quarters · filed 2025-02-27
-$200.30M
derived: sum of 4 quarters · filed 2025-02-27
2023-04-02-$68.90M
10-Q · filed 2024-05-09
-$128.20M
derived: sum of 2 quarters · filed 2025-02-27
-$158.00M
derived: sum of 3 quarters · filed 2025-02-27
-$1.69B
derived: sum of 4 quarters · filed 2025-02-27
2023-01-01-$59.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$89.10M
derived: sum of 2 quarters · filed 2025-02-27
-$1.62B
derived: sum of 3 quarters · filed 2025-02-27
-$1.64B
10-K · filed 2025-02-27
2022-10-02-$29.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
-$1.56B
derived: sum of 2 quarters · filed 2023-11-02
-$1.58B
10-Q · filed 2023-11-02
-$1.68B
derived: sum of 4 quarters · filed 2024-08-01
2022-07-03-$1.53B
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$1.56B
10-Q · filed 2023-08-09
-$1.65B
derived: sum of 3 quarters · filed 2024-08-01
-$1.74B
derived: sum of 4 quarters · filed 2024-08-01
2022-04-03-$24.70M
10-Q · filed 2023-05-04
-$120.70M
derived: sum of 2 quarters · filed 2024-08-01
-$213.90M
derived: sum of 3 quarters · filed 2024-08-01
2022-01-02-$96.00M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01
-$189.20M
derived: sum of 2 quarters · filed 2024-08-01
-$319.50M
10-K/A · filed 2024-08-01
2021-10-03-$93.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04
-$223.50M
10-Q · filed 2022-11-04
2021-07-04-$130.30M
10-Q · filed 2022-08-05
2021-01-03-$63.30M
10-K · filed 2023-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92